NCT06541171View on ClinicalTrials.gov

A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results

Not yet recruitingOBSERVATIONAL
Enrollment

220

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2027

Conditions
Ovarian CancerRecurrent Ovarian Carcinoma
Interventions
OTHER

Magnetic resonance imaging as fpr clinical practice

An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.

Trial Locations (1)

00168

"Fondazione Policlinico Universitaro A. Gemelli IRCCS", Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06541171 - A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results | Biotech Hunter | Biotech Hunter